RETINOSTAT

Welcome to the Brand page for “RETINOSTAT”, which is offered here for Gene therapy and prophylaxis products, gene delivery, gene transfer, gene regulation and gene modulation for the treatment of [ blood disorders, cancers, diseases of the nervous system, ] macular degeneration, diabetic retinopathy, [ diabetes, inflammatory and auto-immune diseases, vascular disorders, ] disorders arising from improper vascularisation and single gene disorders; pharmaceutical substances and preparations for use in the medical industry, vaccines, enzymes and enzyme preparations, anti-apoptopic and angiostatic/angiogenic molecules, retroviral vector and retroviral vector manufacturing preparations, all for use in gene delivery technologies, vector production technologies and neurogenomics products; chemical products for use in medical science, particularly for treatment of disease of the eye, vascular and neovascularisation disorders and retinopathy; pharmaceutical and biochemical preparations for the treatment of macular degeneration and retinopathy [ and angiogenesis; ] instruments and apparatus for the administration of gene and [ antibody-based ] therapy and prophylaxis preparations and substances, pre-filled vials, syringes and injectors for medical purposes;color is not claimed as a feature of the mark.;chemical and biochemical products for use in gene delivery technology, enzymes; chemical products for in-vitro use in laboratories and for analysis in gene delivery technology, micro-organisms, cell cultures, plasmids and cultures of micro-organisms, deoxyribonucleic acid sequences, cloning vehicles and recombinant deoxyribonucleic acid variations thereof, all for in-vivo use in gene delivery technology;scientific and medical research and development; [ engineering services, biotechnology services, biotechnology research in the development of therapeutic and prophylactic products and vaccines; licensing of intellectual property; ] advisory services relating to the research and development of gene therapy; consultation services in the fields of medical and scientific research in the field of professional gene therapy [; medical research and development in the field of vector production technologies ];.

Its status is currently believed to be active. Its class is unavailable. “RETINOSTAT” is believed to be currently owned by “Oxford BioMedica plc”.